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SOLUBLE EPOXIDE HYDROLASE INHIBITION: A NOVEL THERAPEUTIC 
STRATEGY IN ALCOHOLIC LIVER DISEASE 
Jeffrey B. Warner 
July 9th, 2020 
Emerging evidence suggests that soluble epoxide hydrolase (sEH) inhibition is a 
valuable therapeutic strategy for the treatment of numerous diseases. sEH rapidly degrades 
cytochrome P450-produced epoxygenated lipids (epoxy-fatty acids, epFAs), which 
generally exert beneficial effects on several cellular processes. sEH hydrolysis of epoxy-
fatty acids produces dihydroxy-fatty acids which are typically less biologically active than 
their parent epoxide. sEH inhibition has shown efficacy in treating numerous pathologies 
associated with non-alcoholic liver disease, yet no efforts to date have tested the efficacy 
of sEH inhibition in alcoholic liver disease (ALD). Herein, we measured the levels of sEH 
expression and epFAs in human ALD, and assessed the efficacy of the sEH inhibitor t-
TUCB in multiple pre-clinical mouse models of ALD. Mice exposed to ethanol but treated 
with t-TUCB had decreased liver injury, inflammation, and endoplasmic reticulum (ER) 
stress compared to controls, an observation that was reproduced in whole-body sEH 
knockout mice. In vitro, individual epFAs (17,18-EpETE and 19,20-EpDPA) prevented 
hepatocyte apoptosis/ER stress and endotoxin-induced pro-inflammatory cytokine 
production in macrophages. These results suggest the ability of sEH inhibition to prevent 
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alcohol-associated liver injury, inflammation, and ER stress, that is potentially mediated 
by specific epFAs. Future work will determine the efficacy of sEH inhibition in a treatment 
paradigm of sEH inhibitor administration and further elucidate molecular mechanisms.
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  CHAPTER 1 
INTRODUCTION 
Epoxy-Fatty Acids and Soluble Epoxide Hydrolase Activity/Inhibition 
Since their discovery in the 1970s, mammalian epoxide hydrolases (EHs) have 
become an increasingly popular focus of research due to their role in disease pathology [1, 
2]. This family of proteins consists of four enzymes encoded by genes Ephx1-4, where 
Ephx1 and Ephx2 encode microsomal and soluble EHs (mEH and sEH, respectively), and 
Ephx3 and Ephx4 encode EH3 and EH4, which are not well characterized. EHs are 
expressed across all domains of life, including both mammalian and non-mammalian 
animals [3], including insects, frogs, fish, nematodes [4], and plants, protists [5], fungi, and 
several phyla of bacteria (e.g., actinobacteria, proteobacteria, firmicutes, and others [6]). 
EHs catalyze the hydrolysis of epoxides by the addition of water to form vicinal diols. 
Importantly, substrate specificity differs between EHs: mEH generally acts upon toxic 
xenobiotic epoxides, whereas sEH generally acts upon endogenous lipid epoxides [1]. An 
important class of sEH substrates are the cytochrome P450 (CYP450) monooxygenase 
products of omega-3 and omega-6 polyunsaturated fatty acids (PUFAs), herein referred to 
as epoxy-fatty acids (epFAs). This class includes epoxyeicosatrienoic acids (EETs, 
products of arachidonic acid [AA]), epoxyoctadecenoic acids (EpOMEs, products of 
linoleic acid [LA]), epoxyeicosatetraenoic acids (EpEETs or EEQs, products of 
eicosapentaenoic acid [EPA]), and epoxydocosapentaenoic acids (EpDPAs or EDPs, 
products of docosahexaenoic acid [DHA]) (Figure 1). The CYP2C and CYP2J subfamilies 
are primarily responsible for the production of these epFAs [7], which generally exert 
beneficial effects on a number of cellular processes. For example, epFAs can be anti-
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inflammatory [8-10] and anti-fibrotic [11], and can promote the resolution of inflammation 
[12] and tissue regeneration [13]. However, not all epFAs are beneficial – for example, LA 
(an omega-6 fatty acid)-derived 9,10-EpOME and 12,13-EpOME are associated with 
respiratory distress and interfere with neutrophil function following infection [14].  
The potent biological effects of epFAs are abrogated due to their rapid hydrolysis 
by EHs – particularly sEH, the main EH responsible for endogenous lipid epoxide 
degradation [15]. sEH is a dual function enzyme with a C-terminal hydrolase domain and 
N-terminal phosphatase domain. The role of the phosphatase domain is not well 
Figure 1. Endogenous role of soluble epoxide hydrolase. Cytochrome P450 
monooxygenases catalyze the addition of an epoxide ring to polyunsaturated fatty acids, 
including omega-6 arachidonic and linoleic acids (AA and LA, respectively) and 
omega-3 eicosapentaenoic and docosahexaenoic acids (EPA and DHA, respectively). 
Soluble epoxide hydrolase (sEH) rapidly degrades these beneficial epFAs to their 
inactive, less active, or deleterious cognate dihydroxylated fatty acids. EET, 
epoxyeicosatrienoic acid; EpOME, epoxyoctadecenoic acid; EpEET, 
epoxyeicosatetraenoic acid; EpDPA, epoxydocosapentaenoic acid; DiHETE, 
dihydroxyeicosatrienoic acid; DiHOME, dihydroxyoctadecenoic acid; DiHETrE, 
dihydroxyeicosatetraenoic acid; DiHDPA, dihydoxydocosapentaenoic acid. 
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characterized [16], but hydrolase domain-mediated breakdown of epFAs is a well-known 
process considered to deactivate epFAs. Indeed, dihydroxyeicosanoid products of epFAs 
(dihydroxyFAs) are generally less biologically active, inactive, or, in some cases, 
deleterious [17]. Logically, preservation of epFA levels by sEH inhibition is an attractive 
therapeutic option. To this end, numerous sEH inhibitors (sEHIs) have been developed 
using various pharmacophores, and with variable dissociation constants through the 
nanomolar and micromolar ranges. In the last decade, the disubstituted urea 
pharmacophore has gained popularity because of its higher potency than the previous 
generation of inhibitors [18]. Compounds in this class include TPPU, TPAU, APAU, 
TPCU, TUPS, AUCB, and t-TUCB (see Table 2 for full chemical names and Figure 2 for 
chemical structures and full chemical names); these inhibitors are used commonly in 
experimental animal and cell culture models of various pathologies. Indeed, preclinical 
animal models have demonstrated the efficacy of sEHIs in the treatment of atherosclerosis 
[19, 20], kidney injury [21-24], acute lung injury [25-28], inflammatory bowel disease [29-
31], angiogenesis and cancer [32, 33], psychiatric and neurological disorders [34-37], 
sepsis [38], and more. Moreover, there are several clinical trials testing the effectiveness 
of sEHIs in humans. The sEHI GSK2256294 has completed a phase I clinical trial to 
determine its safety, pharmacokinetics, and efficacy in treating glucose intolerance 
(ClinicalTrials.gov NCT03486223) and smoking-related endothelial dysfunction [39]. 
Another compound, AR9281, has also completed phase I clinical trials for hypertension 
and insulin resistance treatment (ClinicalTrials.gov NCT00847899). Another sEHI, 





Table 1. Abbreviations and full chemical names for commonly used sEH inhibitors. 
Inhibitor 














Figure 2. Chemical structures for representative inhibitors. Chemical structures 




There is accumulating evidence that sEH expression is induced in many liver 
pathologies, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic 
steatohepatitis (NASH), liver fibrosis, and portal hypertension (PTH) [40-44]. While much 
effort has been expended to develop treatments, these liver diseases remain a global health 
burden. For example, global prevalence of NAFLD is estimated at roughly one in four [45]. 
Preservation of the remaining epFA pool by sEH inhibition represents an exciting novel 
therapeutic strategy with low adverse effects [46] to address this health crisis. The 
following sections summarize the novel field of sEH inhibition in liver diseases by 
analyzing preclinical studies in several liver pathologies including NAFLD and associated 
metabolic disorders, NASH, and PTH. The reader is encouraged to consult Table 2 for 
categorical information on each key study reviewed.  
 
Table 2. Summary of studies investigating the role of sEH in liver diseases. Listed are 
studies cited in the review, along with details of the experimental design (model, species, 
and sEHI used) and a brief description of the results and mechanism, if available. Changes 
in sEH expression or activity are noted in the results column, where available. 
 
Authors [Ref] Inhibitor Disease Model Result 
Molecular Mechanisms 
In Vivo In Vitro 
Iyer et al. [47] t-AUCB NAFLD 
HFHC 
Diet, Rat 
↓ Insulin Resistance 
↓ Hypertension 
↓ Steatosis 
↓ Liver Hypertrophy 
↓ Cholesterol 
↓ GTT Glucose 
AUC 
N/A 



















↓ Cell Death, in vitro 
↓ BiP, XBP1, CHOP 
↓ Caspase 3, cJUN, 
JNK, p38 






↑ Insulin Signaling, 
in vitro 
↑ sEH Protein 
Lopez-Vicario 








↑ sEH Protein 
↑ IL10, RELMα, 
CD206, 
MGL1 
↑ M2 Polarization 
14,15-EET, 19,20-
EpDPA, and 17,18-
EpETE in Primary 
Hepatocytes: 
↓ Lipid accumulation 
↓ phospho-eIF2α, 
phospho-IRE1α 
↑ LC3II:LC3I ratio 















↓ COX2 Expression 
N/A 





↓ Oxidative Stress 
↓ NFκB 
↓ JNK 
↑ SOD, GPX 
14,15-EET in HepG2 
cells: 




↓ TNFα, IL1β, IL6 




↑ sEH Protein 
↑ Fatty Acid β-
Oxidation Genes 
↑ PPARα Activation 
sEH Inhibition and 
11,12-EET in Primary 
Hepatocytes: 
↑ PPARα Activation 





Mouse ↓ Cholesterol 
↑ AMPK Activation 
↓ SREBP1 
↓ HMG CoA 
Reductase 
12,13-EpOME in vitro: 
↑ phospho-AMPK 
↓ HMG CoA 
Reductase 
Harris et al. 
[51] 








↓ JNK, Caspase 3 
N/A 
Zhang et al. 
[44] 





↓ Oxidative Stress 















↓ Portal Pressure 
↓ Liver Fibrosis 
↓ Liver Endothelial 
Dysfunction 
↑ sEH Protein 
↑ p-eNOS 
↑ NO 
↓ Caveolin 1 
↓ NFkB 
N/A 




↑ sEH Activity by 
Lipidome 
↓ iNOS N/A 






↓ Organ Damage 
↓ Systemic 
Inflammation 





↓ ALT/AST, BUN 
↓ Bacterial CFU’s 
14,15-EET in vitro: 
↓ TNFα, IL1β, IL6 
↑ IL10 
 
sEH Inhibition in Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease 
Epidemiological data show a strong association between NAFLD and metabolic 
syndrome, but the connection between the two is more than correlative: insulin resistance 
and lipid accumulation associated with metabolic disorder contribute directly to NAFLD 
pathogenesis [54]. For example, hepatic steatosis, an early manifestation of NAFLD, is the 
result of accumulation of “benign” lipid vesicles in the liver without significant 
inflammation or cell death and is common in metabolic syndrome patients [55]. From here, 
a minority of patients with NAFLD develop progressive NASH, wherein steatosis is 
accompanied by hepatic inflammation (primarily mediated by neutrophils and 
macrophages/recruited monocytes) and hepatocyte death [56]. NAFLD and NASH patients 
may or may not develop accompanying fibrosis, a complication that increases mortality 
[57]. However, the highest morbidity and mortality in non-alcoholic liver disease patients 
is not due to end-stage liver complications, but rather due to associated cardiovascular 
disease and cancer [58]. 
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There are several pre-clinical studies demonstrating beneficial effects of sEH 
inhibition in NAFLD and associated metabolic abnormalities. A report by Iyer et al. 
investigated the efficacy of sEH inhibition in metabolic syndrome using male Wistar rats 
fed a high carbohydrate, high fat (HCHF) diet ad libitum with or without the sEHI t-AUCB 
administered in the drinking water [47]. Compared to HCHF controls, HCHF rats treated 
with t-AUCB had significant improvements in metabolic endpoints including plasma lipid 
levels and insulin sensitivity. The study also investigated pathological changes related 
specifically to the liver, demonstrating that sEH inhibition by t-AUCB attenuated HCHF 
diet-induced liver hypertrophy, steatosis, and injury (confirmed by decreased lactate 
dehydrogenase and aspartate aminotransferase levels [LDH and AST, respectively], 
plasma biomarkers of liver injury). However, they reported no protection against HCHF 
diet-induced liver immune cell infiltration. This report on the pathogenic role of sEH in 
NAFLD has been corroborated by a host of other studies. For example, Liu et al. used an 
eight-week high fat diet (HFD) feeding to induce NAFLD in C57BL/6 mice, then 
administered t-AUCB for four additional weeks (i.e. a ‘treatment’ paradigm) [40]. Whole-
body sEH knockout (Ephx2-/-) mice were also fed a control or HFD. Compared to controls, 
HFD + t-AUCB mice had decreased steatosis as shown by liver hematoxylin & eosin 
(H&E) staining and reduced liver triglyceride content. Unlike Iyer et al., Liu et al. 
demonstrated a marked improvement in liver inflammation in HFD mice given t-AUCB or 
in Ephx2-/- mice. Specifically, decreased macrophage accumulation as determined by F4/80 
immunohistochemistry and decreased mRNA expression of numerous pro-inflammatory 
cytokines (e.g. TNFα, IL-6, MCP-1, IFNγ) were observed. In this study, t-AUCB was also 
administered in a prevention paradigm, where the inhibitor was added to the drinking water 
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prior to the animals being placed on a longer term 16-week HFD feeding protocol. In this 
paradigm, the NAFLD phenotype was similarly abrogated - decreased liver organ 
hypertrophy, decreased steatosis and liver/plasma triglycerides, and decreased 
inflammatory cytokine expression were reported in this model. Further, markers of 
inflammatory pathway activation (JNK and p38) were reduced. Conversely, when mice 
were injected with adenoviruses encoding human sEH, metabolic syndrome was 
exacerbated – liver/plasma lipids were increased, pro-inflammatory cytokine production 
was increased, and JNK and p38 proteins were increased. sEH inhibition or deletion also 
caused a reduction in HFD-induced adipose tissue inflammation, suggesting a role for the 
adipose-liver axis in sEH-mediated liver pathology. A study by Yao et al. also supports a 
pathogenic role for sEH in NAFLD [49]. Here, a high methionine diet (HMD) was used to 
induce hyperhomocysteinemia (HHcy) and hepatic steatosis. HHcy is prevalent in 
individuals with NAFLD and is considered a significant risk factor [59, 60]. In mice fed an 
HMD, sEH inhibition by TPPU ameliorated hepatic steatosis as shown by liver H&E 
staining and decreased hepatic triglycerides compared to controls, likely due to an increase 
in the expression of β-oxidation genes (Cpt1α, Acox1, and Mcad). 
Mechanistically, evidence generated by Sun et al. suggests that sEH inhibition may 
reduce hepatic inflammation by blocking inflammasome activation [43]. While the 
inflammasome is a key protein complex that regulates the adaptive response of the liver to 
pathogenic challenge, evidence also suggests a deleterious role in numerous liver diseases 
[61]. Sun et al. demonstrated that administration of 4-(5-phenyl-3-{3-[3-(4-
trifluoromethyl-phenyl)-ureido]-propyl} S-pyrazol-1-yl) benzenesulfonamide (PTUPB) 
reduced inflammasome activation, as evidenced by a decrease in Nlrp3/NLRP3 and Asc 
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expression, compared to HFD-fed mice without PTUPB. HFD-induced expression of 
downstream inflammasome targets pro-caspase 1, pro-IL1β, pro-IL18, and caspase 1 p10 
were also decreased by PTUPB [43]. Additionally, administration of PTUPB reduced 
expression of hepatic pro-inflammatory cytokines TNFα, MCP1, and IL-6. It should be 
mentioned that PTUPB is a dual inhibitor of both sEH and cyclooxygenase 2, meaning 
future research may be needed to confirm the role of sEH specifically in inflammasome 
activation. 
 Hepatic endoplasmic reticulum (ER) stress is a known cellular consequence of 
NAFLD and metabolic syndrome. During ER stress, accumulation of unfolded proteins in 
the ER lumen activates the unfolded protein response (UPR), a signaling pathway which 
acts to either mitigate the burden of unfolded proteins or trigger apoptosis [62]. ER stress 
is both a consequence and a driver of liver disease, due to the UPR’s ability to trigger 
inflammation, inflammasome activation, and hepatocyte death [63]. Bettabieb et al. 
demonstrated a significant improvement in liver/adipose ER stress in Ephx2-/- mice and 
wild-type (WT) mice administered TUPS [41]. Specifically, HFD-induced mRNA 
expression of BiP, the ER lumen unfolded protein ‘sensor’, was decreased by sEH 
inhibition or deletion, as was activation of PERK, IRE1α, and ATF6, the three ER 
membrane-bound proteins that activate each of the three branches of the UPR. 
Consequently, expression of downstream effectors of these three branches (e.g. XBP1 
splicing, GADD34, and phopho-eIF2α) was also decreased at the protein level. 
Importantly, protein expression of the pro-apoptotic transcription factor CHOP, which lies 
downstream of all three branches of the UPR, was attenuated as well, indicating the 
pathogenic role of sEH in nearly every step of the UPR.  
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 Lopez-Vicario et al. further corroborated the ability of sEH inhibition to attenuate 
hepatic steatosis and inflammation (e.g. decreased macrophage infiltration, chemokine and 
pro-inflammatory cytokine production, and increased expression of the pro-resolution 
cytokine IL10) [42]. The ER stress associated with NAFLD/metabolic syndrome was also 
attenuated by sEH inhibition in this study as demonstrated by decreased protein levels of 
phosphorylated IRE1α and eIF2α (which lies downstream of PERK), thereby corroborating 
the protection against ER stress previously shown by Bettabieb et al. with a different sEHI. 
One potential contributor to this reduced ER stress is autophagy, a homeostatic process that 
selectively degrades damaged organelles by engulfing and targeting them for lysosomal 
degradation. Autophagy plays a critical role in liver health by degrading lipid droplets 
(lipophagy), glycogen granules (glycophagy), mitochondria and peroxisomes to regulate 
metabolism, and importantly, portions of stressed ER (reticulophagy/ER-phagy) [64, 65]. 
In numerous liver diseases (including NAFLD/metabolic syndrome, ALD, viral hepatitis, 
hepatocellular carcinoma [HCC], and others), autophagy is dysregulated, leading to 
metabolic imbalance and an inability to eliminate damaged cellular components/organelles 
[66]. Lopez-Vicario et al. demonstrated that sEH inhibition rescued autophagy 
dysregulation in a HFD mouse model of NAFLD using the sEHI t-TUCB [42]. 
Specifically, protein expression of autophagy-related indicators Atg12-Atg5 (a protein 
complex) and LC3II were decreased with HFD feeding but significantly rescued with t-
TUCB. 
sEH Inhibition in Hepatic Fibrosis and Portal Hypertension 
 Liver fibrosis is a pathological feature of multiple liver diseases, including NASH, 
severe ALD, viral hepatitis, and cholestatic liver disease. Progressive fibrosis ultimately 
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leads to liver cirrhosis and subsequent liver failure [67]. The scar tissue produced during 
hepatic fibrosis consists of abnormal extracellular matrix (ECM) components deposited by 
activated fibroblasts, typically hepatic stellate cells (HSCs) – although other fibroblasts 
may also play a role [68]. Importantly, fibrosis and inflammation are highly interconnected 
– many of the same cytokines that induce an inflammatory response (e.g. IL6, IL1β, and 
TGFβ) also activate HSCs to trigger liver fibrosis. Evidence also demonstrates that pro-
inflammatory eicosanoids like prostaglandins and leukotrienes can promote liver fibrosis 
[69, 70], whereas epFAs have shown protection against fibrosis in several organs [71]. 
However, studies investigating the role of epFAs and sEH in liver fibrosis are limited.  
One such report by Harris et al. demonstrated the ability of sEH inhibition to 
improve carbon tetrachloride (CCl4)-induced liver fibrosis in mice given TPPU in the 
drinking water [51]. Specifically, quantitation of liver picrosirius red staining (which binds 
collagen) showed significant induction of fibrosis by CCl4 and reversal back to control 
levels by TPPU. More mechanistically, TPPU decreased expression of genes associated 
with HSC activation such as Col1a2, Col3a1, Itag2 (integrin α2), and Tsp2 
(thrombospondin 2). TPPU also decreased both the mRNA expression and activity of 
matrix metalloproteases (MMPs), enzymes that positively correlate with fibrosis. CCl4 is 
also a potent inducer of liver inflammation and ER stress, both of which contribute to HSC 
activation. Harris et al. also showed that TPPU attenuated CCl4-induced markers of 
inflammation (Cxcr4 and Ccr2), ER stress (phospho-PERK, phospho-IRE1α, Atf6, and 
Chop), and fibrosis (Tgfβ1), indicating that sEH inhibition may inhibit liver fibrosis both 
directly by acting on pro-fibrotic mediators and indirectly by acting on contributing factors. 
Use of an additional sEHI (t-TUCB) as well as Ephx2-/- mice validated these results, 
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suggesting a pathological role for sEH in liver fibrosis. Similar protection against CCl4-
induced liver fibrosis and portal pressure were obtained by Zhang et al. with the sEHI t-
TUCB [44]. Specifically, t-TUCB decreased CCl4-induced HSC activation markers (e.g. 
Tgfβ1, αSMA [alpha smooth muscle actin], collagens I and III, and MMPs) and markers of 
inflammation (Il1β, Il6, Tnfα, and Nfκb). In addition, readouts of oxidative stress, another 
cellular consequence of CCl4 administration associated with increased liver fibrosis, 
showed that t-TUCB decreased CCl4-induced malondialdehyde formation and rescued the 
CCl4-mediated loss of superoxide dismutase and glutathione.  
 A study by Deng et al. aimed to determine whether sEH inhibition could also 
ameliorate PTH in rats [52]. PTH is a complication of liver fibrosis characterized by 
alterations in vascular tone and increased intrahepatic vascular resistance (IHVR) which 
increases portal pressure and blood flow, leading to varices, ascites, hepatomegaly, and 
other clinical presentations [72]. This question is also of pertinent research interest due to 
the known role of epFAs, particularly EETs, in promoting vasodilation by activating 
endothelial nitric oxide synthase (eNOS) [73, 74]. Deng et al. used a CCl4 administration 
model of fibrosis and intrahepatic PTH which recapitulates the vascular dysfunction and 
structural abnormalities associated with IHVR [72]. t-TUCB administration significantly 
improved CCl4-induced hemodynamic deficits, significantly decreasing portal pressure, 
portal blood flow, and IHVR while non-significantly decreasing mean arterial pressure. In 
an in situ liver perfusion study to assess endothelial function, the same research group also 
showed t-TUCB rescued the impaired vasorelaxation caused by CCl4. This phenotype was 
accompanied by increased phospho-eNOS protein, nitric oxide levels, and decreased 
caveolin-1 protein (which reduces eNOS activity). In addition to improving hemodynamics 
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and endothelial function, t-TUCB also ameliorated the underlying fibrosis/HSC activation 
and inflammation, as indicated by decreased αSMA and NFκB protein levels, respectively. 
Therefore, this study suggests the ability of sEH inhibition to protect against PTH both by 
directly improving endothelial function and thereby hemodynamics, but also indirectly by 
improving the underlying fibrosis and inflammation.  
sEH Inhibition in Sepsis Models 
One immunological manifestation of severe liver disease is sepsis – a condition 
characterized by dysregulated response to inflammation following invasion of gut bacteria 
and associated bacterial products [75]. Like PTH, sepsis is a common a complication of 
cirrhosis. Cirrhosis patients are more susceptible to bacterial infection than the general 
population [76], and later-stage (decompensated) cirrhosis is associated with yet a higher 
risk [77]. Given the anti-inflammatory role of some epFAs, sEH is a logical target for 
treating the underlying inflammation associated with sepsis. To this end, Fife et al. 
investigated the ability of sEH inhibition to attenuate sepsis in a lipopolysaccharide (LPS) 
injection model with the sEHI AUDA administered by osmotic pump or by using Ephx2-/- 
mice [53]. Despite the ability of sEHIs to attenuate inflammation in the previous NAFLD 
models [40, 42, 43], AUDA and genetic sEH deletion had limited ability to attenuate LPS-
induced hepatic pro-inflammatory cytokine production (IL6, iNOS, TNFα) in the early 
phase of inflammation following LPS insult. By contrast, protection against LPS-induced 
inflammation has been demonstrated in a study by Schmelzer et al. where a higher LPS 




A study by Chen et al. provides further evidence that sEHI-mediated protection 
against sepsis is model-dependent by showing the beneficial effects of TPPU in a surgical 
cecal ligation and puncture (CLP) model [38]. This polymicrobial CLP sepsis model is 
arguably more comparable to human sepsis than LPS injection because it causes spillage 
of numerous fecal bacteria into the peritoneum, whereas LPS injection only introduces a 
single pathogen-associated molecular pattern [79]. Chen et al. showed mice that received 
the sEHI TPPU by oral gavage daily for five days prior to the procedure had a 20% 
improvement in CLP-induced mortality compared to vehicle controls (all control mice died 
within the 48-hour period following the procedure). Additionally, TPPU improved signs 
of dysfunction in several organs, including the liver. Specifically, liver leukocyte 
infiltration and liver injury were significantly decreased compared to controls. 
Systemically, TPPU attenuated CLP-induced blood and peritoneum bacterial load and 
subsequently attenuated the inflammatory “cytokine storm” that follows, with decreases in 
systemic TNFα, IL1β, and IL6 levels following the surgery. Further, in a phagocytosis 
assay, TPPU increased RAW264.7 macrophage phagocytosis of fluorescent beads, 
indicating improved macrophage function. Collectively, these data suggest that sEH 
inhibition is a useful therapy in sepsis, but that model and phase of inflammation are critical 
factors determining its efficacy. 
Molecular Mechanisms of sEHI-Mediated Protection against Liver Diseases 
sEH may be responsible for the metabolism of some toxic xenobiotics, but the 
evidence reviewed here suggests a pathogenic role for sEH in liver diseases (Table 2). 
Indeed, many of the studies reviewed report an induction of sEH expression at the 
mRNA/protein level or an increase in sEH activity in different liver pathologies [40-44, 
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52, 53]. The efficacy of sEHIs generally lies in decreasing sEH activity, rather than 
decreasing expression of the gene/protein, although in some systems sEHIs do in fact 
modulate sEH protein levels. For example, Zhang et al. and Sun et al. reported that sEH 
inhibition by t-TUCB and PTUPB significantly reduced sEH protein in animals with PTH 
and NAFLD, respectively [43, 44]. By contrast, Lopez-Vicario showed an increase in sEH 
protein in two different mouse genotypes after t-TUCB administration [42]. Translational 
curiosities aside, the protection against liver diseases afforded by sEHIs is likely due to 
preservation of epFAs which would otherwise be hydrolyzed by sEH. Indeed, the health 
benefits of epFAs derived from omega-3 and omega-6 PUFAs have long been 
demonstrated. In 1999, the anti-inflammatory properties of AA-derived EETs were 
discovered and linked to down-regulation of NFκB [8]. EETs also promote organ 
regeneration/compensatory growth (including regeneration of the liver), wound healing, 
and retina/cornea vascularization [13]. EpFAs have also been implicated in preventing 
inflammation and promoting the resolution of inflammation [12]. While sEH inhibition is 
the more logical approach pharmacologically, boosting epFA pools by increasing their 
synthesis rather than preventing their degradation also improves disease phenotype. 
Evidence shows that liver overexpression of the epFA-producing Cyp2j2 improves 
NAFLD endpoints like steatosis, inflammation, and oxidative stress [48]. 
 In vitro studies suggest a link between individual epFAs and mechanisms 
underlying liver pathology such as lipid/cholesterol accumulation, insulin signaling, ER 
stress, autophagy, and inflammation. With respect to lipids and cholesterol, Mangels et al. 
showed a beneficial role for LA-derived 12,13-EpOME in cholesterol homeostasis in 
HepG2 cells [50]. In this study, 12,13-EpOME, but not 12,13-DiHOME, decreased protein 
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expression of HMG CoA reductase, the rate limiting enzyme in cholesterol biosynthesis, 
by increasing expression of its inhibitor AMP-activated protein kinase. Lopez-Vicario et 
al. showed that palmitic acid (PA)-induced lipid accumulation in primary mouse 
hepatocytes was abrogated by AA-derived 14,15-EET, EPA-derived 17,18-EpETE, and 
DHA-derived 19,20-EpDPA [42]. EpFAs are also implicated in insulin signaling, another 
critical factor in metabolic syndrome and NAFLD. Bettabieb et al. treated HepG2 cells 
with unspecified EETs and EpOMEs, which enhanced basal and insulin-stimulated insulin 
receptor phosphorylation and protein kinase B phosphorylation (which induces glucose 
transport) [41]. With respect to ER stress, the same EETs and EpOMEs showed no effect 
on PA-induced ER stress, but interestingly, the sEH hydrolysis products (DiHETEs and 
DiHOMEs) exacerbated ER stress (as shown by phospho-IRE1α, phospho-eIF2α, and 
phospho-PERK levels) suggesting that sEHI-mediated protection may come in the form of 
epFA preservation or dihydroxyFA depletion [41]. Interestingly, Lopez-Vicario et al. were 
able to demonstrate attenuated ER stress with 14,15-EET, 17,18-EpETE, and 19,20-
EpDPA in primary hepatocytes. These three epoxides also increased the LC3II:LC3I 
protein ratio, indicating enhanced activation of autophagy. With respect to inflammation, 
Chen et al. showed the anti-inflammatory properties of epFAs in the liver, demonstrating 
that 14,15-EET decreased PA-induced pro-inflammatory cytokine production (e.g. TNFα, 
IL6, and IL1β) in HepG2 cells [48]. This was accompanied by decreased NFκB signaling, 
consistent with previous studies connecting epFAs to NFκB blockade [8]. In addition to 
hepatocytes, cell culture studies also support a mechanistic role for epFAs in 
monocytes/macrophages. Chen et al. investigated 14,15-EET’s ability to alter cytokine 
release and phagocytosis in RAW264.7 murine macrophages. 14,15-EET had no effect on 
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phagocytic ability when administered alone but did decrease LPS-induced expression of 
pro-inflammatory cytokines TNFα, IL1β, and IL6 [38]. By contrast, LA-derived 9,10-
EpOME and 12,13-EpOME were shown to induce pro-inflammatory cytokine expression 
(Il6 and Mcp1) in RAW264.7 cells in a dose-responsive manner [80]. Interestingly, sEH 
hydrolysis deactivated these LA-derived epFAs; corresponding dihyroxyFAs 9,10-
DiHOME and 12,13-DiHOME did not influence Il6 and Mcp1 expression. These results 
suggest an immunomodulatory role for sEH in either preventing or permitting macrophage 
activation, depending on the epFA or dihydroxyFA considered. 
Mechanistically, epFAs may act via several receptors, including peroxisome 
proliferator-activated receptors alpha and gamma (PPARα and PPARγ, respectively) [10, 
81]. These PPARs are considered therapeutic targets for the treatment of liver diseases like 
NAFLD due to their role in regulating glucose and lipid metabolism [82]. Subsequently, 
inhibition of PPARγ abrogates the beneficial effects of sEH inhibition in various diseases 
[83-85], and inhibition of PPARα abrogated the protective effect of TPPU on steatosis in 
mice in the study by Yao et al. [49]. At the level of individual epFAs, competition binding 
studies show that EETs (specifically 5,6-EET, 8,9-EET, 11,12-EET, and 14,15-EET) bind 
PPARγ with dissociation constants in the low micromolar range [81]. EPA-derived 17,18-
EpEET was similarly shown to act through PPARγ to exert its anti-inflammatory effects 
[10]. Further, 11,12-EET, 14,15-EET, and 14,15-DiHETE, the hydrolysis product of 
14,15-EET, were shown to activate PPARα in a luciferase reporter system, with 14,15-
DiHETE activating PPARα at a level nearly three times higher than that of 14,15-EET, 
suggesting that epFAs and dihydroxyFAs may interact with nuclear receptors differently 
[49, 86]. Some sEHIs are may even act as PPARα ligands themselves [87], suggesting that 
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sEHI-mediated control of inflammation and lipid/glucose metabolism through PPAR 
receptors may be controlled both directly by the sEHI and indirectly by epFAs and 
dihydroxyFAs. 
Another important point to consider is that there may be differences in the 
biological activities of epFAs based on the parent PUFAs. Data reviewed here suggests 
that omega-3-derived epFAs may have greater efficacy than omega-6-derived epFAs in 
blocking cellular characteristics of liver pathology. This idea is analogous to the more 
established concept that omega-3 PUFAs themselves are beneficial in liver disease, 
whereas omega-6 PUFAs are more pathogenic [88]. Specifically, Lopez-Vicario et al. 
showed that the omega-3 (EPA/DHA)-derived lipids included in their study (17,18-EpETE 
and 19,20-EpDPA) were more efficacious than the omega-6 (AA)-derived 14,15-EET in 
reducing PA-induced lipid accumulation/ER stress and promoting autophagy [42]. The 
differential effects of omega-3 vs. omega-6-PUFA-derived epFAs are often not directly 
considered; additional research in this area will likely address this question in the future. 
Knowledge Gaps  
While the initial discovery of epoxide hydrolases occurred about fifty years ago, 
the pathogenic role of sEH in liver diseases has been defined only recently. Clearly, sEH 
inhibition is an attractive therapeutic option in a spectrum of liver diseases, but future 
research in some key areas are needed to further elucidate its applications, limitations, and 
molecular mechanisms. One area that should be addressed is sex-specific responses to sEH 
inhibition in liver diseases. None of the studies reviewed here included female animals, 
despite the well-known sexual dimorphism of some liver diseases such as NAFLD in both 
humans and rodents [89]. Importantly, evidence suggests estrogens can down-regulate sEH 
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expression, meaning females may have higher baseline epFA levels affording some 
protection against liver disease, although no studies have addressed this question directly 
[90-92]. Future research should also address the efficacy of sEH inhibition in additional 
liver diseases like viral hepatitis, cholestatic liver disease, and HCC. These diseases share 
some characteristics with the liver diseases reviewed here (e.g. chronic inflammation, 
oxidative stress, ER stress, etc.), characteristics which epFA preservation may attenuate 
[93-95]. Next, the pool of epFAs is quite a large one, however the role and underlying 
mechanisms of only few have been investigated so far. Future research should incorporate 
additional epoxides from multiple PUFAs to elucidate key mediators of liver diseases, and 
to better understand whether omega-3 PUFAs truly do give rise to more beneficial epoxides 
than omega-6 PUFAs. Another important area to consider is that sEH is a dual-function 
enzyme with two domains, a C-terminal hydrolase domain (which sEHIs target), and an 
N-terminal phosphatase domain. While the hydrolase domain is well-studied, the 
phosphatase domain is not, meaning its potential contribution to liver pathology is 
unknown. Future studies should consider that the phosphatase activity remains active even 
after addition of sEHIs but is inactivated by genetic sEH deletion: this may help elucidate 
any differences in phenotype between sEHI-treated and Ephx2-/- animals. 
The ultimate goal of sEHI research in preclinical animal models is translation to 
human diseases. It is important to mention that humans have various polymorphisms in the 
EPHX2 gene associated with increases or decreases in sEH activity [96, 97]. Specifically, 
substitution of lysine 55 with arginine (Lys55Arg) is associated with higher hydrolase 
activity, whereas substitution of Arginine 287 with glutamine (Arg387Gln) is associated 
with decreased hydrolase activity. These functional variants are associated with altered risk 
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of cardiovascular disease and insulin sensitivity [98-100], and may contribute to 
heterogeneity in response to sEHI therapy between individuals. Clinical trials are 
nonetheless underway involving sEHIs for the treatment of insulin resistance, glucose 
intolerance, hypertension, endothelial dysfunction, and pain. Given the early success of 
these compounds, future clinical trials should help bring sEHIs into the market for liver-
specific diseases in the coming years. 
sEH Inhibition and ALD 
Despite the growing research efforts to apply sEH inhibition to liver diseases, no 
studies to date have addressed the efficacy of sEH inhibition in ALD. Chronic, excessive 
consumption of ethanol (EtOH) is the key etiological driver of ALD and produces 
significant changes in liver physiology. Like NAFLD, ALD begins with steatosis, a 
Figure 3. sEH inhibition in liver diseases: knowns and unknowns. sEH inhibitors 
preserve levels of endogenously produced epFAs by preventing their sEH hydrolysis. 
sEH inhibition improves disease phenotype in non-alcoholic liver disease, non-
alcoholic steatohepatitis, hepatic fibrosis, cirrhotic portal hypertension, and cirrhotic 
sepsis. Individual epFAs are shown to improve insulin resistance, inflammation, 
autophagy, oxidative stress, and endoplasmic reticulum stress, suggesting a mechanistic 
link between sEH inhibitors and protection against liver diseases. No prior research has 
investigated sEH inhibition in ALD, viral hepatitis, hepatocellular carcinoma, or 
cholestatic liver disease. PUFAs, polyunsaturated fatty acids; CYP, cytochrome P450 
2J/2C families; sEH, soluble epoxide hydrolase; sEHI, soluble epoxide hydrolase 
inhibitor; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic 




manifestation present in nearly all heavy drinkers [101]. However, in some drinkers, EtOH-
induced steatosis may further progress to inflammation (alcohol-associated 
steatohepatitis), and end-stage ALD complications like cirrhosis, and HCC. Early-stage 
liver manifestations of ALD (i.e. steatosis and steatohepatitis) are reversible with cessation 
of EtOH consumption [102]; however, end-stage liver manifestations of ALD (i.e. cirrhosis 
and HCC) are irreversible and associated with significant mortality [101]. Importantly, 
ALD pathology shares several pathological mechanisms with NAFLD, such as 
inflammation and ER stress [101]. The innate immune system is activated following EtOH-
induced bacterial translocation from the gut and EtOH-induced liver cell death, leading to 
release of damage-associated molecular patterns, activation/recruitment of immune cells 
in the liver, and further production of reactive oxygen species and inflammatory cytokines 
[101]. EtOH consumption also leads to activation of the UPR and prolonged, pathological 
ER stress that further promotes liver inflammation, cell death, and steatosis [103]. sEHIs 
and epFAs have been demonstrated to attenuate inflammation, ER stress, and cell death 
associated with other liver diseases including NAFLD, suggesting that sEH inhibition may 
be a valid strategy in the management of ALD as well [38, 41, 43, 44, 51].  
The purpose of the present research is to fill this knowledge gap by investigating 
sEH alterations in human ALD and testing the efficacy of sEH inhibition in ALD using 
pre-clinical animal models of the disease. We hypothesize that sEH inhibition by 
pharmacological or genetic means will attenuate the liver injury and inflammation 
associated with EtOH administration in mouse models of ALD. Generating data in support 
of this hypothesis will not only contribute to development of novel therapeutic strategies 




MATERIALS AND METHODS 
Experimental Animals 
Male mice (C57BL/6) were purchased from The Jackson Laboratory (Bar Harbor, 
ME) and housed in a specific pathogen-free animal facility accredited by the Association 
for Assessment and Accreditation of Laboratory Animal Care under a protocol approved 
by the University of Louisville Institutional Animal Care and Use Committee (Nos. 15423 
and 18418 to Dr. Irina Kirpich). Ephx2-/- mice were obtained from the UC Davis Mouse 
Biology Program.  Ephx2 knockout was confirmed by genotyping and Western blot for 
sEH with antibodies obtained from Dr. Bruce D. Hammock. The room was maintained on 
a 12-hour light/dark cycle.  
Experimental Design 
Two mouse models were employed that mimic human drinking patterns and 
development of ALD, the first being an acute-on-chronic (10+1) model where mice are 
provided an all liquid diet for 10 days followed by a single EtOH “binge” on day 11, 
delivered by oral gavage (5g/kg) 9h prior to euthanasia (n = 7-9 mice/group, Figure 4A). 
The second model is a chronic EtOH administration model where mice are provided an all 
liquid diet for six weeks, but with no EtOH binge. The mice are acclimated to the liquid 
diet with the following concentrations of EtOH (% v/v): 0% x 2d; 2% x 2d, 4% x 7d, 5% 
x 7d, and 6% x 21d. The mice were euthanized at the end of the feeding period (n = 7-15 
mice/group, Figure 4B). The control and EtOH liquid Lieber DeCarli diets were purchased 
from Bio-Serv (Flemington, NJ) (EtOH diet, cat no. F1341SP and control, F1340SP). The 
EtOH and control diets are identical and isocaloric with the exception that maltodextrin is 
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substituted for EtOH in the control diet. Some mice received the sEH inhibitor 4-[[trans-4-
[[[[4-Trifluoromethoxy) phenyl] amino] carbonyl]-amino] cyclohexyl] oxy]-benzoic acid 
(t-TUCB) in the liquid diet, whereas other mice received only the EtOH vehicle (which 
was an insignificant source of EtOH) as a control. For each model, 8-12-week-old C57BL/6 
males were randomized into one of four groups: pair-fed (PF), PF + t-TUCB, EtOH, and 
EtOH + t-TUCB. t-TUCB was a generous gift of Dr. Bruce Hammock (UC Davis) and was 
dissolved in EtOH and then added to the liquid diet at a concentration of 7.5µg/ml. This 
level was chosen because it is estimated to deliver a dose of 3mg/kg/day/mouse based on 
average food consumption determined from previous experiments. 
 
Assessment of Liver Damage 
At the termination of each experiment, mice were deeply anesthetized with 
ketamine/xylazine and blood collected from the inferior vena cava with heparinized 
syringes and transferred to microcentrifuge tubes. The plasma fraction was prepared by 
centrifugation at 2,000xg for 10 min, aliquoted, and immediately stored at -80°C. Plasma 
Figure 4. Feeding model schemes. A. Schematic representation of the chronic-binge 
“10+1” Lieber DeCarli EtOH feeding model. B. Schematic representation of the chronic 




alanine aminotransferase (ALT) activity was determined using the ALT/GPT reagent 
(Thermo Fisher, Waltham, MA). Portions of liver tissue from the left hepatic lobe were 
snap-frozen in liquid nitrogen and stored at -80°C or were fixed in 10% neutral buffered 
formalin and embedded in paraffin for histological assessment. Formalin-fixed, paraffin-
embedded liver sections were stained with hematoxylin and eosin (H&E) for overall 
morphology and steatosis, chloroacetate esterase (CAE) for neutrophil infiltration, terminal 
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) for apoptosis, and F4/80 
for macrophage infiltration. 
qPCR 
Mouse total liver RNA was isolated with Trizol reagent (Thermo Fisher) and 
cDNAs were synthesized with qScript cDNA Supermix (Quanta Biosciences, Beverly, 
MA) followed by digestion with DNase (Thermo Fisher). qPCR reactions were performed 
on the cDNA equivalent of 10 ng of input RNA using PerfeCTa SYBR Green Fast Mix 
(Quanta Biosciences) on an Applied Biosystems 7900HT instrument (Foster City, CA). 
Data was analyzed by the ΔΔCT method using 18S as the calibrator [104]. Primer 
sequences are listed in Table 3. Analysis of Xbp1 splice variant ratio was performed by 
standard PCR followed by gel electrophoresis, as previously described [105].  
Table 3. qPCR primer sequences. m designates mouse, h designates human. 
Target Forward Primer (5’ to 3’) Reverse Primer (3’ to 5’) 
mCpt1a GCTGCACTCCTGGAAGAAGA GGAGGGGTCCACTTTGGTAT 
mTnf-α GTGATCGGTCCCCAAAGG GGTGGTTTGCTACGACGTG 
mFasn CAGTGGGTGGACTCTCTGAAG GACAGCAGGATACACCGAATC 
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mIl-6 TGGAAATGAGAAAAGAGTTGTGC CCAGTTTGGTAGCATCCATCA 
mXbp1 ACTTGCACCAACACTTGCCATTTC CAAGGTTCACTGCCTGTAATG 
mXbp1-Sp* GAGAACCAGGAGTTAAGAACACG GAAGATGTTCTGGGGAGGTGAC 
mCxcl1 GGAAGTGTGATGACTCAGGTTTGC GATGGTTCCTTCCGGTGGTTTCTTC 
hCyp2j2 CACAGGGACCCCACAGAGTG AGGCATGCCCGCTTTCCTAT 
hCyp2c19 TCGATGGACATCAACAACCCT ACTGTTGGTTTTGCTTTTCCTTCTC 
*Primers used for determining Xbp1 splicing. 
Western Blotting 
Mouse whole protein liver lysates were prepared by homogenization in 
radioimmunoprecipitation buffer supplemented with Halt™ protease and phosphatase 
inhibitors (Thermo Fisher) followed by centrifugation at 10,000g for 10 minutes to remove 
insoluble material. Protein concentrations were determined by Bradford assay [106] using 
reagent from Bio-Rad (Hercules, CA) with bovine serum albumin as a standard. 60µg of 
protein was diluted in 4X sample buffer (BioRad) and loaded onto a BioRad Criterion™ 
pre-cast acrylamide gel (Biorad cat. no. 5671127) and separated at 100 volts for 90 minutes. 
Proteins were electro-blotted onto a polyvinylidene difluoride membrane at 70 volts for 
two hours, blocked with 3% milk in TBST for 30 minutes, and incubated overnight with 
commercially available anti-C/EBP homologous protein (CHOP), inositol-requiring 
enzyme-1α (IRE1α), or phosphorylated IRE1α (Phospho-IRE1α) antibodies (Thermo 
Fisher). The membranes were washed and incubated in horseradish peroxidase-conjugated 
secondary antibodies and imaged using a BioRad Chemidoc™ imaging system. 
Plasma t-TUCB Analysis 
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 Mouse plasma levels of t-TUCB were measured by mass spectrometry in the 
laboratory of Dr. Bruce D. Hammock at the University of California, Davis.  
Liver triglycerides 
 Mouse hepatic lipids were extracted with chloroform and methanol as previously 
described [107] and triglycerides (TGs) were measured using reagents from Thermo Fisher 
Scientific Inc. (Waltham, MA) according to the manufacturers’ instructions. 
Targeted Lipidomic Analysis of epFAs in Human and Mouse Liver Tissue 
 Explanted human liver tissue was procured from the Johns Hopkins University 
Transplant Center and analyzed by the Wayne State University Lipidomic Core Facility as 
previously described [108]. A similar analysis was conducted on mouse livers isolated from 
mice in our chronic EtOH feeding model. 
Cell Culture 
 HepG2 human hepatoma cells were cultured and treated with 1µM 19,20-EpDPA 
(Cayman Chemical, Ann Arbor, MI) for 24 hours in a 96-well plate format plated at 10,000 
cells per well. Cells were then stained with Annexin V Alexa Fluor 647 conjugate (Life 
Technologies, Carlsbad, CA) and Fluo-4 AM (Thermo Fisher Scientific, Waltham, MA) 
for 15 minutes. Mean ring/circle average fluorescent intensity was analyzed for each well 
by cellomics analysis with the Thermo Fisher ArrayScan VTI HCS instrument (Thermo 
Fisher Scientific, Waltham, MA). Experiments were performed in eight replicate wells. 
 RAW264.7 macrophages were cultured and treated with for 21h with 1µM 17,18-
EpETE or 19,20-EpDPA (Cayman Chemical, Ann Arbor, MI) solubilized in DMSO (final 
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DMSO concentration was 0.034%) in a 24-well plate format plated at 175,000 cells per 
well. Cells were then challenged with 10ng/mL LPS for 3 h and then total RNA was 
isolated as per the manufacturer’s instructions (Qiagen, Germantown, MD) and cDNA was 
synthesized for qPCR analysis of pro-inflammatory cytokine mRNA analysis as described 
above. Experiments were performed in three replicate wells. 
Statistical Analysis 
Data are shown as mean ± standard error of the mean (SEM). GraphPad Prism 8 
software (GraphPad Software, San Diego, CA) was used to perform one sample Student’s 
t-tests(for two group comparison) or one-way ANOVA tests (for more than two groups) 
for data following a normal distribution and Mann-Whitney and Kruskal Wallis H tests for 






Lipidomic Analysis of Human Liver Tissue 
 To determine whether there are alterations in sEH activity and an imbalance in the 
pool of epFAs/dihydroxyFAs in human ALD, we obtained explanted human liver tissue 
from both patients with severe alcoholic hepatitis (sAH, n = 7), a severe clinical 
manifestation of ALD, and control non-ALD/AH patients (n = 5) from Drs. Z. Sun and A. 
Ahmadi through the John Hopkins University Clinical Resources Center for Alcoholic 
Hepatitis Investigations (under grant 1R24AA025017-01). We then performed targeted 
lipidomic analysis with these liver samples. The average model end-stage liver disease 
(MELD) score for the ALD patients was 37. Figure 5A shows representative liver 
histopathology by H&E staining, which is characterized by steatosis and immune cell 
infiltration. Targeted lipidomics analysis showed that several epFAs derived from AA (5,6-
EET and 11,12-EET) and DHA (16,17-EpDPA and 19,20-EpDPA) were significantly 
decreased in ALD patients’ liver tissue relative to healthy control tissue (Figure 5C). We 
then tested whether the decrease in these EpFAs was accompanied by an increase in 
EPHX2 (the gene encoding human sEH) expression. To this end, we assayed the mRNA 
expression of EPHX2 by qPCR in our liver samples and discovered that ALD patients’ 
liver tissue had a significant increase in the expression of EPHX2 compared to controls 
(Figure 5B). Additionally, these patients’ liver tissue also had lower expression of several 
CYPs involved in epoxygenation of fatty acids, including CYP2J2, CYP2C19, and 
CYP4A11, as measured by qPCR (Figure 5D). The combination of increased sEH and 
decreased CYP expression is consistent with a decrease in epFA levels, given that CYPs 
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are responsible for their production and sEH is responsible for their degradation. We 
previously demonstrated that this pattern was recapitulated in a mouse model of ALD 
[108], thus providing a system whereby we can investigate the efficacy of sEH inhibition 
in experimental ALD. 
 
sEH Inhibition Improved Liver Injury in Two Mouse ALD Models 
To assess the efficacy of sEH inhibition in experimental ALD, we administered the 
sEH inhibitor t-TUCB orally in the liquid diet in two mouse models of ALD that 
recapitulate human drinking behavior: a chronic EtOH administration model and an acute-
Figure 5. Liver tissue from Human ALD patients has decreased levels of epFAs.  
A. Representative H&E-stained liver sections from a patient with alcoholic hepatitis 
(MELD score 34, right) and a control patient (left), 200X magnification. B. qPCR 
analysis of mRNA expression of EPHX2 in control and ALD human liver tissue. C. 
Targeted lipidomics analysis of liver tissue epFAs in control and ALD human liver 
samples. The top and bottom graphs are levels of AA-derived and DHA-derived epFAs, 
respectively. D. qPCR analysis of mRNA expression of epFA-producing CYP450s in 
control and ALD human liver tissue. All data are represented as mean ± standard error 
of the mean, with significance considered as p < 0.05. 
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on-chronic (10+1) model. The chronic model mimics long-term EtOH consumption and 
produces a modest increase in liver injury and inflammation driven by macrophages [109]. 
The 10+1 model mimics a common pattern of drinking behavior among patients with ALD, 
which is to consume a steady amount of EtOH chronically with a sudden escalation 
(chronic-binge behavior). This model is characterized by significant liver injury, steatosis 
and inflammation driven by neutrophil infiltration [110]. Figure 6A outlines these two 
ALD models. There was no effect of t-TUCB on body weights or food consumption in 
either of the experiments (data not shown). 
To determine whether t-TUCB increased the levels of liver epFAs, we performed 
targeted LC-MS lipidomics analysis (Wayne State Lipidomics Core Facility) and assessed 
the ratio of 19,20-EpDPA to its cognate dihdroxyFA 19,20-DiHDPA and the ratio of 17,18-
EpETE to its cognate diol, 17,18-DiHETrE as an indirect measure of sEH activity (Figure 
6B). As expected, there was an increase in the epFA:dihydroxyFA ratio for each pair in 
mice administered t-TUCB compared to vehicle controls, indicating decreased sEH 
activity in the former. Importantly, sEH inhibition by t-TUCB significantly decreased 
EtOH-induced liver injury in the 10+1 model to a lesser degree in the chronic model as 
determined by plasma ALT activity (Figure 6C). To determine if variations in t-TUCB 
consumption between experiments was responsible for this effect, we analyzed plasma 
levels of t-TUCB and correlated them to plasma ALT activity (Figure 6D). We saw no 
positive correlation between plasma t-TUCB levels and plasma ALT activity, indicating 









Figure 6. sEH Inhibition Decreased Liver Injury in Multiple Mouse Models of 
ALD. A. Schematic representation of experimental mouse models of ALD. Upper 
scheme represents the 10+1 model of EtOH administration, lower scheme represents 
the chronic EtOH model. B. Targeted lipidomic analysis of mouse liver tissue from the 
chronic experiment. Red bars represent mice from the EtOH group and blue bars 
represent mice from the EtOH + t-TUCB group. Data are shown as the ratio of epFA to 
dihydroxyFA for 17,18-EpETE/17,18-DiHETrE and 19,20-EpDPA/19,20-DiHDPA on 
the left and right, respectively. C. Plasma ALT activity from the 10+1 model of EtOH 
administration. D. Plasma ALT activity from the chronic model of EtOH administration. 
All data are represented as mean ± standard error of the mean, with significance 
considered as p < 0.05. 
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t-TUCB did not Affect Hepatic Steatosis 
 Hepatic steatosis is a hallmark of ALD. To determine if protection against steatosis 
is a mechanism by which t-TUCB decreased liver injury, we analyzed lipid accumulation 
by H&E histopathology and liver TG analysis. In the chronic model, we observed a marked 
EtOH-induced increase in hepatic fat content on H&E-stained liver sections (Figure 7A), 
accompanied by a significant increase in hepatic TGs (Figure 7B). In this model, t-TUCB 
had only a small, non-statistically significant ability to reduce hepatic steatosis, and, 
Figure 7. sEH Inhibition does not Affect Hepatic Steatosis. A and D. Representative 
images of H&E-stained liver sections from mouse livers from the chronic EtOH 
administration model and 10+1 EtOH administration model, respectively, 200X 
magnification. B and E. Analysis of liver triglyceride levels, normalized to liver weight, 
in the chronic EtOH administration model and 10+1 EtOH administration model, 
respectively. C and F. qPCR analysis of liver mRNA expression of Fasn and Cpt1α 
from mouse livers in the chronic EtOH administration model and 10+1 administration 
model, respectively. All data are represented as mean ± standard error of the mean, with 
significance considered as p < 0.05. 
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interestingly, t-TUCB significantly increased hepatic TGs in the PF + TUCB group. In 
addition to analyzing hepatic TG levels, we also assayed the expression of several key 
genes regulating fatty acid homeostasis (Figure 7C). Analysis by qPCR revealed that the 
expression of fatty acid synthase (Fasn) was increased in the EtOH-fed groups in the 
chronic model but was not reduced effect by t-TUCB. By contrast, the EtOH-mediated 
decrease in carnitine palmitoyltransferase 1 alpha (Cpt1α), a gene related to fatty acid beta 
oxidation, was significantly rescued by t-TUCB. In the 10+1 model, we observed a similar 
EtOH induction of hepatic steatosis by evaluation of H&E-stained liver sections and liver 
TG analysis (Figure 7D and Figure 7E). t-TUCB similarly caused a slight reduction in 
hepatic steatosis but was not statistically significant. qPCR analysis of Fasn and Cpt1α 
expression showed no significant difference between mice administered t-TUCB vs. 
vehicle controls (Figure 7F). 
sEH Inhibition Attenuated Chronic EtOH-Associated Liver Inflammation 
To determine whether protection against inflammation is a mechanism by which t-
TUCB decreased liver injury, we performed CAE staining and qPCR analysis of pro-
inflammatory cytokine production. In the chronic model, we observed a decrease in the 
number of liver neutrophils, as determined by CAE staining, in the livers of mice treated 
with t-TUCB in both PF and EtOH-fed mice (Figure 8A and Figure 8B). Additionally, 
EtOH-induced expression of the pro-inflammatory cytokine Cxcl1 was significantly 
reduced by t-TUCB in EtOH-fed mice. EtOH administration also induced expression of 
the pro-inflammatory cytokine Il6, which was rescued by t-TUCB, although these changes 




sEH Inhibition Attenuated Chronic EtOH-Associated Liver ER Stress 
 ER stress can contribute to ALD pathogenesis, and is implicated in liver 
inflammation, apoptosis, and steatosis [111]. Therefore, we assayed activation of the UPR 
by determining the expression of key genes involved in this process. In the chronic model, 
we found strong induction of CHOP protein expression in the livers of EtOH-fed mice as 
determined by Western blot (Figure 9A and Figure 9B). In EtOH + t-TUCB treated mice, 
Figure 8. sEH Inhibition Improves Chronic EtOH Consumption-Associated Liver 
Inflammation. A. Representative images from CAE-stained liver sections from the 
chronic EtOH administration model. Arrows indicate CAE-positive cells (neutrophils), 
400X magnification. B. Quantification of CAE staining. Ten digital fields were 
analyzed for CAE-positive cells per mouse liver section. C and D. qPCR analysis of 
Cxcl1 and Il-6 expression in mouse livers from the chronic EtOH administration model, 
respectively. All data are represented as mean ± standard error of the mean, with 
significance considered as p < 0.05. 
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however, there was a significant reduction in CHOP protein. We also determined the 
expression of phospho-IRE1α, which induces CHOP expression, and found no significant 
differences between vehicle and t-TUCB treated mice (data not shown). Further, we 
assayed for differences in splicing of Xbp1 mRNA from its unspliced to its spliced form 
(unspliced, Xbp1u, spliced, Xbp1s). It is difficult to determine differences in mRNA 
expression of the two variants of Xbp1 by qPCR because they differ by only 26 nucleotides. 
Therefore, we used standard PCR with followed by high-resolving gel electrophoresis and 
densitometry to determine differences in abundance between Xbp1u and Xbp1s (Figure 
Figure 9. sEH Inhibition Improves Chronic EtOH-Associated Liver ER Stress. A. 
Western blot analysis of CHOP protein in livers of mice in the chronic EtOH 
administration model. GAPDH served as the loading control. B. Densitometry analysis 
of CHOP expression. Data are normalized to GAPDH expression. C. Standard qPCR 
and gel electrophoresis analysis of Xbp1 splicing. Upper bands are unspliced Xbp1 
(Xbp1u), bottom bands are spliced Xbp1 (Xbp1s). D. Densitometry analysis of the 
Xbp1s:Xbp1u ratio. All data are represented as mean ± standard error of the mean, with 
significance considered as p < 0.05. 
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9C). In the chronic model, EtOH increased the Xbp1s:Xbp1u ratio which was reduced to 
PF levels in the EtOH + t-TUCB group (Figure 9D).  
Genetic Ablation of sEH Similarly Decreased Liver Injury and Inflammation 
 In order to validate our results with pharmacological inhibition of sEH by t-TUCB 
administration on ALD, we used whole-body sEH knockout (Ephx2-/-) mice in the 10+1 
model of EtOH administration. As with mice administered t-TUCB, we observed a 
reduction in liver injury by plasma ALT activity in EtOH-fed Ephx2-/- mice compared to 
EtOH-fed WT controls (Figure 10A). We next aimed to determine whether the liver 
phenotype observed in t-TUCB treated mice with respect to steatosis and inflammation 
was recapitulated in Ephx2-/- mice. To this end, we stained liver sections with H&E to 
evaluate steatosis and used ELISA to measure the levels of hepatic pro-inflammatory 
cytokines CXCL1 and IL6. As with t-TUCB treated mice, Ephx2-/- mice fed EtOH had no 
significant difference in hepatic steatosis by H&E staining (Figure 10B and Figure 10C). 
We observed a similar trend in liver inflammation: Ephx2-/- mice fed EtOH had a significant 
decrease in liver CXCL1 protein and a decrease in liver IL6 protein, although the reduction 







EpFAs Prevented Hepatocyte Apoptosis and Macrophage-Mediated Cytokine 
Production 
 To determine whether individual epFAs contribute to improvements in cellular 
pathologies associated with ALD, we conducted an in vitro analysis. We first treated 
serum-starved HepG2 cells with 19,20-EpDPA for 24 hours. To analyze apoptosis and ER 
stress, we then stained the cells with Annexin V-FITC and Fluo4-AM, respectively, and 
measured fluorescence by cellomics (Figure 11A). 19,20-EpDPA significantly decreased 
the Annexin V signal compared to control, indicating a decrease in HepG2 apoptosis 
(Figure 11C and Figure 11D). Similarly, 19,20-EpDPA-treated HepG2 cells had a 
Figure 10. Genetic Ablation of sEH Similarly Attenuates Liver Injury and 
Inflammation. A. Plasma ALT activity. B. Representative images of H&E-stained liver 
sections from WT and Ephx2-/- mice, 100X magnification. C. Quantitation of liver 
steatosis by analysis and grading of H&E-stained liver sections. D and E. ELISA 
analysis of Cxcl1 and Il-6 protein levels in mouse livers from WT and Ephx2-/- mice, 
normalized to mL liver homogenate. All data are represented as mean ± standard error 
of the mean, with significance considered as p < 0.05. 
39 
 
significant decrease in Fluo-4 AM fluorescence (a measure of intracellular free calcium), 
indicating decreased ER stress by intracellular free calcium (Figure 11B and Figure 11D). 
 Next, we aimed to determine whether epFAs could prevent LPS-induced pro-
inflammatory cytokine expression macrophages. To this end, we pre-treated RAW264.7 
macrophages with 17,18-EpETE or 19,20-EpDPA for 21 hours prior to a 3-hour LPS 
challenge, then assayed cytokine expression by qPCR (Figure 12A). LPS administration 
caused a nearly 300-fold increase in Cxcl1 mRNA and a nearly 30-fold increase in Tnfα 
mRNA in RAW264.7 cells compared to a DMSO control. Remarkably, cells treated with 
Figure 11. 19,20-EpDPA Prevents Hepatocyte Cell Death. A. Schematic 
representation of cell culture experiments. Serum-starved HepG2 cells were exposed to 
19,20-EpDPA for 24 hours prior to Fluo4 and Annexin V staining and cellomics 
analysis. Cells were plated in 10 replicate wells. B. Representative fluorescent images 
of Fluo4 and Annexin V-stained HepG2 cells, 400X magnification. C and D. 
Quantification of Fluo4 and Annexin V fluorescent intensity by cellomics, respectively. 
All data are represented as mean ± standard error of the mean, with significance 
considered as p < 0.05. 
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LPS + 17,18-EpETE or LPS + 19,20-EpDPA had reduced Cxcl1 mRNA expression by 
roughly a third compared to LPS alone (Figure 12B). Similarly, these two epFAs also 
significantly decreased LPS-induced Tnfα mRNA expression by almost a half compared to 
LPS alone (Figure 12C). 
  
Figure 12. EpFAs Prevent Macrophage-Mediated Pro-Inflammatory Cytokine 
Release. A. Schematic representation of cell culture experiment. RAW264.7 cells were 
exposed to 17,18-EpETE or 19,20-EpDPA 21 hours prior to a 3-hour LPS challenge, 
then harvested for qPCR analysis of pro-inflammatory cytokine expression. Cells were 
plated in triplicate wells. B and C. qPCR analysis of mRNA expression of Cxcl1 and 
Tnfα in RAW264.7 cells. All data are represented as mean ± standard error of the mean, 






EpFAs have emerged as mediators of inflammation, steatosis, autophagy, ER 
stress, and more [8, 12, 13, 42], and are rapidly deactivated by sEH hydrolysis [1, 15]. sEH 
inhibition has been demonstrated to be a viable treatment strategy for several diseases, 
including those of the liver, although prior to the current study, no studies had applied sEH 
inhibition to the prevention of ALD. Importantly, in human ALD samples, we found a 
decrease in the epFA pool which was accompanied by increased EPHX2 expression. 
Therefore, we hypothesized that sEH inhibition may act to preserve the remaining epFA 
pool, thereby attenuating liver injury and inflammation. In our models, both 
pharmacological sEH inhibition by t-TUCB and whole-body genetic ablation of sEH 
prevented ALD outcomes, including liver injury, inflammation, and ER stress, while 
having no significant effect on hepatic steatosis. These findings suggest sEH may be a 
novel drug target in ALD, an important finding, given that there are currently no FDA-
approved therapies for ALD. Our findings also corroborate previous reports that sEH 
inhibition is effective in treating liver inflammation and ER stress, which are common 
pathogenic mechanisms in multiple liver diseases [62, 112]. 
In order to determine a patient population that may benefit most from sEH 
inhibition, we used two pre-clinical mouse models of ALD that recapitulate different 
severities of human ALD. The chronic model mimics many early features of ALD such as 
hepatic steatosis, macrophage-driven inflammation, and injury [113], whereas the chronic-
binge 10+1 model recapitulates manifestations of end-stage ALD such as acute liver injury 
and neutrophil infiltration [110, 114]. Interestingly, we discovered that between the two 
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models, sEH inhibition afforded better protection against liver injury in the chronic-binge 
model. Liver injury in the chronic binge model is primarily driven by neutrophil infiltration 
[114], meaning that the beneficial effects of sEH inhibition in ALD may be primarily anti-
inflammatory, which is consistent with evidence of the anti-inflammatory effects of epFAs 
[38, 43, 44, 48]. 
We found no significant effects of sEH inhibition on EtOH-induced hepatic 
steatosis. However, in the chronic model, we did observe a slight protection against fat 
accumulation by t-TUCB that was accompanied by a similar minor rescue of the EtOH-
induced decrease in Cpt1α expression. Cpt1α encodes a carnitine palmitoyltransferase 
critical in regulating beta oxidation, the major pathway of fatty acid ester degradation in 
the fatty liver [115]. By contrast, we saw no protection against EtOH-induced expression 
of lipogenic fatty acid synthase (Fasn). A static level of Fasn expression coupled with 
increased Ctp1 may indicate a preference for fatty acid breakdown rather than synthesis 
in t-TUCB-treated mice, although our histopathology provides only weak evidence for this 
in both pharmacological and genetic ablation of sEH. These data indicate that protection 
against fatty liver degeneration is likely not a major mechanism of sEH-mediated reduction 
in liver injury in our models, despite improvements demonstrated by others in steatosis by 
sEHIs or CYP2J2 overexpression in non-alcoholic liver diseases [40, 42, 43, 47-49].  
sEH inhibition decreased neutrophil-driven infiltration in both PF and EtOH-fed 
mice in our chronic model. Neutrophils are critical mediators of the EtOH-mediated innate 
immune response that suppress bacterial infection and clear damaged cells, but also 
contribute to liver injury and fibrosis through the production of reactive oxygen species, 
proteases, pro-inflammatory cytokines such as Il-6, and neutrophil-attracting chemokines 
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such as Cxcl1 [112]. The expression of these cytokines was decreased by both t-TUCB and 
genetic ablation of sEH in our whole-body knockout mice. Taken together, these data 
suggest that reduction of inflammation is a major mechanism by which t-TUCB affords 
protection against liver injury, in line with numerous studies showing decreased liver 
inflammation in other liver diseases mediated by sEHIs [38, 40, 43, 44]. 
As with NAFLD, ER stress is a contributor to ALD pathogenesis that is marked by 
activation of the UPR, which can ultimately lead to steatosis, hepatocyte apoptosis, and 
subsequently, inflammation [111, 116, 117]. sEH inhibition by t-TUCB decreased splicing 
of Xbp1u to  Xbp1s, which is an active transcription factor that can induce expression of 
pro-apoptotic transcription factor CHOP [118], thereby linking ER stress to hepatocyte cell 
death and liver inflammation. Indeed, our t-TUCB-mediated protection against ER stress 
was accompanied by a decrease in inflammation. This finding is consistent with previous 
reports indicated attenuated ER stress by sEHI administration in NAFLD and liver fibrosis 
[41, 42, 51]. ER stress is also highly connected to steatosis; ER stress is not only a product 
of steatosis but a driver of it as well [117]. Interestingly, we found that while sEH inhibition 
abrogated markers of ER stress, there was no considerable protection against steatosis, 
indicating that while steatosis and ER stress may contribute to each other in a sort of 
‘vicious cycle’, sEH inhibition largely affected ER stress alone. 
While the pool of epFAs is large and these lipid mediators are produced from 
numerous PUFAs, our in vitro studies identified several key epFAs that may drive our in 
vivo protection against liver injury, namely, EPA-derived 17,18-EpETE and DHA-derived 
19,20-EpDPA. Numerous previous reports highlight the ability of these epFAs to improve 
liver disease outcomes in cell culture [42]. Our data suggest the ability of these epFAs to 
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protect against liver injury by acting on multiple cell types, specifically, hepatocytes and 
macrophages. 19,20-EpDPA reduced hepatocyte cell death, a pathological feature of ALD 
that contributes to liver injury [119]. This was accompanied by reduced hepatocyte ER 
stress, corroborating previous evidence that individual epFAs (14,15-EET, 17,18-EpETE, 
and 19,20-EpDPA) decreased activation of the UPR in primary mouse hepatocytes [42]. 
Further, 17,18-EpETE and 19,20-EpDPA prevented the LPS-induced release of pro-
inflammatory chemokines/cytokines Cxcl1 and Tnfα from immortalized macrophages. In 
this experiment we used LPS to stimulate cytokine release because LPS is a major bacterial 
endotoxin produced by gut flora that translocates to the liver following EtOH-induced 
leaky gut [120]. Liver macrophages like KCs respond to bacterial signals such as LPS to 
mediate innate immunity in the liver and are the main sources of pro-inflammatory 
cytokine production [121, 122]. Previous studies show that epFAs can modulate PA-
induced or baseline macrophage cytokine release [48, 80], but our study is the first to show 
that epFAs can decrease cytokine release in response to LPS. These in vitro experiments 
suggest that sEH inhibition, through preservation of epFAs like those tested here, may act 
to reduce the chronic inflammation associated with EtOH consumption by acting on both 
hepatocytes, to prevent cell death, and macrophages, to prevent the release of inflammatory 
mediators. 
 While these results suggest a pathogenic role for sEH in ALD and t-TUCB as a 
potential therapeutic, this study is not without its limitations. First, the t-TUCB drug 
administration paradigm used here was preventative, meaning the inhibitor was given 
throughout the duration of the study. A previous non-alcoholic liver disease study used a 
treatment paradigm where the sEHI was administered after establishing liver injury and 
45 
 
still showed significant protection [40], meaning both paradigms may be efficacious. Our 
future work will address whether treatment with t-TUCB after EtOH-induced liver injury 
is established can still attenuate liver injury, inflammation, and ER stress. Second, we used 
whole-body sEH knockout mice to validate our results with t-TUCB in a genetic model. 
sEH knockout mice lack expression of both the C-terminal hydrolase domain and the N-
terminal phosphatase domain. Therefore, it is impossible to determine whether any effects 
we observed in sEH knockout mice were due to a lack of hydrolase activity, phosphatase 
activity, or both. The biological role of the phosphatase activity remains largely unknown, 
although in vitro studies have demonstrated that lipids such as farsenyl pyrophosphate, 
sphingosine-1-phosphate, and lysophosphatidic acid act as substrates [123-125]. These 
lipid phosphates are involved in cell signaling, growth, and survival, and act as components 
of the cell membrane [125]. Lysophosphatidic acid, further, has been implicated in the 
development of liver fibrosis and liver cancer [126, 127]. Efforts to develop phosphatase 
domain inhibitors have recently begun [128]; our future work will aim to investigate this 
domain in the context of ALD using these compounds. In future research we will also 
consider using liver-specific sEH knockout mice as opposed to whole-body knockout mice 
to study the effects of loss of sEH inhibition within the context of the liver alone. sEH is 
expressed is many tissues [129], meaning whole-body loss of sEH expression may have 





SUMMARY AND CONCLUSIONS 
 sEH inhibition is a promising therapeutic strategy for the treatment of numerous 
diseases, including early-stage liver diseases like simple steatosis and end-stage liver 
diseases like cirrhosis and sepsis. Our work suggests that ALD is another candidate liver 
disease that may benefit from sEH inhibition, given that human ALD patients had 
decreased liver epFAs and increased liver EPHX2 expression. A commonly used sEHI, t-
TUCB, prevented liver injury, inflammation, and ER stress in chronic and acute-on-chronic 
EtOH administration mouse models of ALD. In vitro, several epoxides derived from 
omega-3 PUFAs prevented hepatocyte cell death and expression of pro-inflammatory 
cytokines in macrophages. Continued research to evaluate sEH inhibition in ALD with t-
TUCB administered in a treatment paradigm as well as investigation of the N-terminus 
phosphatase domain of sEH will help promote translation of sEH inhibition to the clinic in 
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